UPCOMING INVESTOR CONFERENCES

Marseille, France, January 7, 2019, 7:00 AM CET

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events in the first quarter 2019:

- **LifeSci Advisors 1x1 Meetings surrounding the J.P. Morgan Annual Healthcare Conference** – San Francisco, January 7-10, 2019
- **Oddo BHF Forum** – Lyon, January 10-11, 2019
- **Degroof Petercam’s Healthcare Seminar** – Brussels, January 31, 2019
- **Leerink Partners Annual Global Healthcare Conference** – NYC, February 27 - March 1, 2019
- **Credit Suisse Global Healthcare Conference** – London, March 5-6, 2019
- **Oppenheimer Annual Healthcare Conference** – NYC, March 19-20, 2019

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.innate-pharma.com/en/investors).

**About Innate Pharma:**

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:

<table>
<thead>
<tr>
<th>ISIN code</th>
<th>FR0010331421</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticker code</td>
<td>IPH</td>
</tr>
<tr>
<td>LEI</td>
<td>9695002Y8420ZB8HJE29</td>
</tr>
</tbody>
</table>

Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

**Investors**

**Innate Pharma**
Dr. Markus Metzger / Danielle Spangler / Jérôme Marino
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com

**International Media**

**Consilium Strategic Communications**
Mary-Jane Elliott / Jessica Hodgson
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com

**French Media**

**ATCG Press**
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com